SkinBioTherapeutics plc (AIM: SBTX), shares fell around 30% after the skin health-focused life sciences company announced the resignation of its chief executive officer, Stuart Ashman.
Ashman stepped down following his suspension by the board pending an investigation into matters relating to his conduct. The company said it is carrying out a full review with the support of professional advisers.
Non-executive chairman Martin Hunt will temporarily take on the role of executive chairman, working alongside the board and leadership team to ensure business continuity.
SkinBioTherapeutics has also launched a search for an interim CEO to be appointed as soon as possible, while simultaneously beginning the process of recruiting a permanent chief executive.
The company said it will provide further updates to the market and shareholders in due course, and that no additional comment will be made at this stage.
For more information please contact:
|
SkinBioTherapeutics plc |
